Roivant’s experimental lung disease drug mosliciguat produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in a phase 2 trial of patients with pulmonary hypertension associated with interstitial lung disease, the highest PVR reduction reported in a randomized controlled pulmonary hypertension trial, according to a Sept. 8 news release.
Here are five things to know:
- The PHocus trial included 135 patients across 87 sites in 20 countries. Patients received once-daily inhaled mosliciguat or placebo.
- At week 16, pulmonary vascular resistance decreased 51.3% among patients receiving mosliciguat and increased 6.6% among those receiving placebo, resulting in a 56.3% placebo-adjusted reduction.
- Mosliciguat also produced a 35.2-meter placebo-adjusted improvement in six-minute walk distance at week 16.
- NT-proBNP decreased 53.2%, or 357.7 pg/mL, compared with placebo at week 16. Cough was reported in 12.1% of patients receiving mosliciguat and 18.2% of those receiving placebo.
- Pulmovant has initiated the phase 3 PHrontier trial, which is expected to enroll approximately 375 patients worldwide. Mosliciguat is a potential first-in-class, once-daily inhaled soluble guanylate cyclase activator.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
